Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.
Scientists are combining immunotherapy agents to try to jump-start the immune system against solid tumors in children.
When Dana-Farber’s Catherine Wu, MD, was a newly minted physician in the mid-90s, there was just one major form of immunotherapy for cancer.
Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.
Prestigious prize goes to researchers who identified B cells and T cells and others who invented the HER2 targeted cancer therapy Herceptin.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Betting on basic science is leading to breakthroughs in immune checkpoint inhibitors, CAR-T, targeted therapies, cancer vaccines and more.
“Don’t eat me” proteins are “like invisibility cloaks for the cancer,” preventing white blood cells from detecting and devouring tum...
“There were so many things that were outside of my control, so I decided to focus on the things that I could do something about.”
NKTR-214 plus Opdivo has been granted an FDA breakthrough therapy designation for advanced melanoma.
New research suggests that inducing necroptosis in or around tumor cells can help the immune system rid the body of cancer cells.
An interview with Michael Kaplan, president and CEO of the Melanoma Research Alliance, about curing the deadliest skin cancer
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.